Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, today announced that Dr. Kristopher Wentzel ...

The company expects revenue to grow in the mid to high single digits in FY26 but has not offered specific margin guidance for the year.

The company projects revenue growth of mid- to high single digits in FY26 compared with an 8.5% increase in FY25 ...

Dystrophic epidermolysis bullosa (DEB) is one of the main subtypes of epidermolysis bullosa, a group of genetic skin disorders characterized by varying degrees of fragility in the skin and mucous ...

Press Release Distributed by ABNewswire.com To view the original version on ABNewswire visit: Nasopharyngeal Cancer Pipeline ...

Viking Therapeutics offers leaner operations, lower complexity, faster trial execution, and less execution risk. Learn more ...

Checkpoint Therapeutics Inc. defeated investor claims it concealed the likelihood US regulators would deny its skin cancer ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Macquarie has reaffirmed its ‘outperform’ rating on Sun Pharmaceutical Industries Ltd. and raised its target price to Rs ...

A new generation of checkpoint inhibitors is emerging, with some showing more promise than others. From recent TIGIT failures ...